Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

20.71
-0.6200-2.91%
Post-market: 20.50-0.2100-1.01%19:49 EDT
Volume:2.03M
Turnover:42.45M
Market Cap:2.86B
PE:-18.19
High:21.65
Open:21.42
Low:20.45
Close:21.33
52wk High:27.34
52wk Low:9.57
Shares:138.26M
Float Shares:118.91M
Volume Ratio:0.84
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1384
EPS(LYR):-5.0048
ROE:-37.11%
ROA:-5.96%
PB:5.48
PE(LYR):-4.14

Loading ...

Arrowhead doses first patient in YOSEMITE trial

TIPRANKS
·
Jul 08

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of RNAi Therapeutic Zodasiran for Treating Homozygous Familial Hypercholesterolemia

Reuters
·
Jul 08

H.C. Wainwright Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Jul 01

Piper Sandler Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Jun 24

Arrowhead Pharmaceuticals Completes Enrollment in Phase 3 Studies for Plozasiran, Awaits FDA Review with Decision Expected by November 2025

Reuters
·
Jun 23

Bernstein Keeps Their Hold Rating on Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Jun 20

Arrowhead Pharmaceuticals Launches Phase 1/2a Clinical Trial of ARO-ALK7 for Obesity Treatment

Reuters
·
Jun 02

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Pharma Mar SA (OtherPHMMF)

TIPRANKS
·
May 27

Arrowhead Pharmaceuticals Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
May 20

Stock Track | Arrowhead Pharmaceuticals Soars 10% Pre-market on Stellar Q2 Earnings, Beating Expectations

Stock Track
·
May 16

UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating

MT Newswires Live
·
May 14

Arrowhead Shares Rise After 2Q Earnings Beat

Dow Jones
·
May 13

Stock Track | Arrowhead Pharmaceuticals Soars 12.74% on Stellar Q2 Earnings, Beating Expectations

Stock Track
·
May 13

Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 13

RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
May 13

Arrowhead Pharmaceuticals: Hold Rating Amid Promising Developments and Regulatory Uncertainties

TIPRANKS
·
May 13

Hold Rating for Arrowhead Pharmaceuticals Amid Revenue Gains and Market Uncertainties

TIPRANKS
·
May 13

Stock Track | Arrowhead Pharmaceuticals Soars 10% Pre-market on Stellar Q2 Earnings, Beating Expectations

Stock Track
·
May 13

Stock Track | Arrowhead Pharmaceuticals Soars 10% Pre-Market on Stellar Q2 Earnings Beat

Stock Track
·
May 13

Arrowhead Pharmaceuticals Inc. Releases Transcript of Fiscal 2025 Second Quarter Conference Call

Reuters
·
May 13